Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 85

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 85
---
, the Company did not have any cash equivalents.

As
of June 30, 2025, the Company did not have deposits in excess of federally insured limits.

Research
and Development

The
Company incurs research and development (“R&D”) costs during the process of researching and developing technologies
and future offerings. The Company expenses these costs as incurred unless such costs qualify for capitalization under applicable
guidance. The Company reviews acquired R&D and licenses to determine if they should be capitalized or expensed under U.S.
GAAP standards.

Below
is a disaggregation of R&D expenses:

    For
    the three
 months Ended

    For
the three
 months Ended 

    For
                                    the six 
months Ended

    For
    the six
 months Ended

    June
    30, 2025

    June
    30, 2024

    June
    30, 2025
     
    June
    30, 2024

    Consultant
     
    $
    107,408
     
    $
    107,357
     
    $
    195,663
     
    $
    137,390

    Lab Materials

    457

    1,452

    1,062

    1,452

    Lab Cell Storage

    15,795

     27,272

    31,223

    51,398

    Chemistry Manufacturing
    and Controls (“CMC”)

    388,629

    (133,780
    )
    
    470,799

    169,617

    IP Services

    2,525

    10,654

    10,365

    119,704

    Total
     
    $
    514,814
     
    $
    12,955
     
    $
    709,112
     
    $
    479,561

Fair
Value Measurements and Fair Value of Financial Instruments

The
Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the
principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

    ●
    Level 1 Inputs are
    unadjusted quoted prices in active markets for identical assets